, plasmacytoid DCs, and T cells. We isolated and analyzed the immune functions of CD11b/ cCD45 glioma-infiltrating microglia/macrophages (GIMs) from postoperative tissue specimens of glioma patients. Although GIMs expressed substantial levels of Toll-like receptors (TLRs), they did not appear stimulated to produce pro-inflammatory cytokines (tumor necrosis factor a, interleukin 1, or interleukin 6), and in vitro, lipopolysaccharides could bind TLR-4 but could not induce GIM-mediated T-cell proliferation. Despite surface major histocompatibility complex class II expression, they lacked expression of the costimulatory molecules CD86, CD80, and CD40 critical for T-cell activation. Ex vivo, we demonstrate a corresponding lack of effector/activated T cells, as glioma-infiltrating CD8 T cells were phenotypically CD8CD25-. By contrast, there was a prominent population of regulatory CD4 T cells (CD4CD25FOXP3) infiltrating the tumor. We conclude that while GIMs may have a few intact innate immune functions, their capacity to be stimulated via TLRs, secrete cytokines, upregulate costimulatory molecules, and in turn activate antitumor effector T cells is not sufficient to initiate immune responses. Furthermore, the presence of regulatory T cells may also contribute to the lack of effective immune activation against malignant human gliomas. Neuro-Oncology 8, 261-279, 2006 (Posted to Neuro-Oncology [serial online], Doc. D06-00002, June 14, 2006 DOI: 10.1215 DOI: 10. /15228517-2006 Keywords: costimulation, human glioma, macrophages, microglia, regulatory T cells, tumor Neuro-Oncology ■ j U LY 2 0 0 6 M alignant gliomas are the most common type of primary brain tumors, and glioblastoma multiforme (GBM) 3 accounts for more than 50% of all intracranial gliomas (Davis et al., 2001) . Although GBMs are immunogenic tumors (Fathallah-Shaykh et al., 1998; Holladay et al., 1994; Ridley, 1977) , they are not eradicated by the immune system. Previously characterized impairments in glioma patient immunity have included low peripheral lymphocyte counts, reduced delayed-type hypersensitivity reactions to recall antigens, and impaired mitogen-induced blastogenic responses by peripheral blood mononuclear cells (PBMCs) (Heimberger et al., 2000) . The modulation and down-regulation of T-cell function by immunosuppressive cytokines such as transforming growth factor b (TGF-b) and interleukin 10 (IL-10) elaborated by malignant gliomas has been previously characterized (Roussel et al., 1996) . TGF-b and IL-10 are known potent inhibitors of macrophage function (Bogdan and Nathan, 1993; Tsunawaki et al., 1988) and of microglia production of nitric oxide synthase, NF-B activation, RANTES, and pro-inflammatory cytokines (Aloisi, 2001; Hu et al., 1999; Vincent et al., 1997) . However, even when these factors are neutralized, efficacious immune responses still cannot be generated (Luscher et al., 1994) . Furthermore, many subtypes of gliomas and cancers metastasizing to the brain do not secrete these immunosuppressive cytokines, yet still cannot generate efficacious immune responses, which indicates that other factors or cell types are involved in the lack of immunological responses.
M alignant gliomas are the most common type of primary brain tumors, and glioblastoma multiforme (GBM) 3 accounts for more than 50% of all intracranial gliomas (Davis et al., 2001) . Although GBMs are immunogenic tumors (Fathallah-Shaykh et al., 1998; Holladay et al., 1994; Ridley, 1977) , they are not eradicated by the immune system. Previously characterized impairments in glioma patient immunity have included low peripheral lymphocyte counts, reduced delayed-type hypersensitivity reactions to recall antigens, and impaired mitogen-induced blastogenic responses by peripheral blood mononuclear cells (PBMCs) (Heimberger et al., 2000) . The modulation and down-regulation of T-cell function by immunosuppressive cytokines such as transforming growth factor b (TGF-b) and interleukin 10 (IL-10) elaborated by malignant gliomas has been previously characterized (Roussel et al., 1996) . TGF-b and IL-10 are known potent inhibitors of macrophage function (Bogdan and Nathan, 1993; Tsunawaki et al., 1988) and of microglia production of nitric oxide synthase, NF-B activation, RANTES, and pro-inflammatory cytokines (Aloisi, 2001; Hu et al., 1999; Vincent et al., 1997) . However, even when these factors are neutralized, efficacious immune responses still cannot be generated (Luscher et al., 1994) . Furthermore, many subtypes of gliomas and cancers metastasizing to the brain do not secrete these immunosuppressive cytokines, yet still cannot generate efficacious immune responses, which indicates that other factors or cell types are involved in the lack of immunological responses.
Innate immunity is the initial antigen-nonspecific response that results in the rapid production of effector cytokines that in turn mature and activate antigenpresenting cells (APCs). One of the most important prerequisites for the immune activation of effector T-cell responses is the presence of functional APCs that process and present tumor antigens, secrete specific cytokines and chemokines, and abundantly express costimulatory molecules essential for initiating and/or propagating tumor-directed T cells (Banchereau and Steinman, 1998) . Immature APCs use Toll-like receptors (TLRs) to recognize microbial or nonself tissue factors. TLR expression is a critical component of mediating innate immune responses to any infectious or traumatic challenge and activating adaptive immune responses. More specifically, the bacterial wall component lipopolysaccharide (LPS) activates through TLR-4 and the cluster of differentiation (CD) molecule CD14, peptidoglycan through TLR-2, dsRNA through TLR-3, and CpG through TLR-9 (Iwasaki and Medzhitov, 2004) . Activation through the TLR results in maturation of the APC, increasing the expression of surface costimulatory molecules and cytokine production (Hemmi et al., 2000) .
The activation of T cells requires two signals: The first signal is provided by the interaction of the T-cell receptor and major histocompatibility complex (MHC)/ antigen complex, and the second signal is provided by the interaction of CD28 on the T cell and the costimulatory molecules CD80 (B7-1) or CD86 (B7-2) on the APC. In addition, CD40 is constitutively expressed on APCs while its ligand CD154 (CD40L) is expressed on activated T cells. The CD40-CD154 interaction provides a costimulatory signal to the APC (reverse costimulation), thereby augmenting the ability of APCs to present antigen and to deliver positive costimulatory signals, which in turn promotes T-cell activation (Tan et al., 1999) . While naive T cells have been shown to be capable of entry into the CNS (Brabb et al., 2000; Krakowski and Owens, 2000) , where they would require mature APC-mediated priming for activation, studies have also demonstrated that primed T cells can infiltrate and be maintained in murine brain tumors (Calzascia et al., 2003 (Calzascia et al., , 2005 . In such situations, repeat stimulation and rerecognition of antigen by the T cells have proved necessary for tumor responses to be generated and to trigger migrant T cells to carry out their effector function (Gabrilovich et al., 1996; Oxenius and Bachmann, 1997) . In either of these scenarios, if the APCs failed to provide appropriate stimulation, they could induce T-cell anergy and thereby contribute to the failure of the immune response.
The role and subtype of APCs involved in priming effector T cells within a malignant human glioma are unknown, but candidates have included microglia, monocytes/macrophages, B lymphocytes, and dendritic cells (DCs), in the latter of which there are two main subpopulations: myeloid (M-DCs) and plasmacytoid (P-DCs). Although microglia express MHC class I, controversy exists as to whether they also express MHC class II (Heimberger et al., 2000) ; thus it is unclear whether microglia can prime T-cell responses. Murine microglia have been shown to express the mRNA for all TLRs (TLR 1-9) (Olson and Miller, 2004) and can be strongly activated after in vitro stimulation with their specific agonists, especially LPS, which includes mounting a strong inflammatory cytokine response (Ebert et al., 2005) . Studies have suggested that murine microglia can activate CD41 helper T cells (McMahon et al., 2005) and have antigen-presenting capabilities (Juedes and Ruddle, 2001; Ulvestad et al., 1994) . However, little is known about the immune performance and interactions of human microglia in the immunosuppressive glioma microenvironment, in part because of the scarcity of fresh human glioma tissue and the technical difficulty in obtaining pure microglia from CNS tissue. Previous analyses have relied on postautopsy cell isolations, primary microglial cultures, or rodent studies, which may not truly characterize these cells within human brain tumors.
Rodent microglia have been defined as having a CD11b/c1CD45Low phenotype, macrophages as having a CD11b/c1CD45High phenotype, and lymphocytes as having a CD11b/c-CD45High phenotype (Badie and Schartner, 2000; Ford et al., 1995) . Although macrophages are believed to be activated microglia within the CNS, no distinct and universally accepted histological marker has been described in human brain tissue that can definitively distinguish macrophages from microglia. Previously, isolation of microglia from rodents has been performed using a series of Percoll gradients (Amersham Biosciences, Uppsala, Sweden) where the microglia were isolated from the interphase between the 1.065-and CD14 and HLA DP, DQ, and DR (Dako Cytomation, Carpinteria, Calif.); TLR-1, TLR-2, TLR-3, and TLR-4 (eBiosciences, San Diego, Calif.); and CD1c and BDCA-2 (Miltenyi Biotec, Auburn, Calif.). For intracellular cytokine staining, we used PE-labeled or FITC-labeled antibodies against interferon  (IFN-), TNF-a, IL-1b, IL-6, IL-10, and IL-12 (R&D Systems, Minneapolis, Minn.); and FOXP3 (eBiosciences). Appropriate isotype controls were used for every antibody.
Staining Fresh Tumor Specimens
Freshly isolated tumor tissue was mechanically dissociated, passed through a 70-mm-pore-size mesh, and washed. Nonspecific binding was blocked by incubation with purified anti-CD16 antibody (Pharmingen) and rabbit serum (Invitrogen, Carlsbad, Calif.) for 20 min and then stained with the fluorescence-labeled primary antibody or isotype control for 30 min at 4°C.
GBM or normal CNS tissue was stained with a three-color isotype control panel, which included FITC mouse immunoglobulin G1 (mIgG1), PE mIgG1, and APC mIgG1, as described in Results. Since the isotype controls were identical for both, we have displayed under Results only the isotype controls performed on GBMs. Approximately 1 3 10 6 live, gated events based on forward scatter and side scatter were assessed during fluorescence-activated cell sorting (FACS) using the FACsCalibur instrument (BD Biosciences, San Jose, Calif.) and analyzed with CellQuest software (BD Immunocytometry Systems, San Jose, Calif.). The double-negative populations were not present because of the gating strategy that was employed as described in Fig. 1 .
Isolation of Microglia/Macrophages from Human Brain Tumor Tissue
To purify microglia/macrophages from human brain tissue, we adapted a modified Percoll-gradient isolation technique previously described in rodent CNS tissue (Ford et al., 1995) after evaluation of the phenotype of each interphase. This technique minimized artificial activation of the microglia/macrophages, and these cells were isolated usually within 3 h of surgical resection. Briefly, after resection, freshly isolated tumor or normal brain tissue was mechanically dissociated through a stainless steel sieve. The dissociated material was centrifuged, washed, and layered onto an isotonic Percoll gradient diluted with PBS to 1.095 g/ml and overlaid with 1.03 g/ml Percoll. After centrifugation, the cell layer between the 1.095-g/ml and 1.03-g/ml layers was removed, washed, layered on top of a second gradient (2-ml increments of isotonic Percoll diluted to 1.12, 1.088, 1.072, 1.065, and 1.03 g/ml), and centrifuged. Microglia/ macrophages were collected from the interface between the 1.065-g/ml and 1.03-g/ml layers and washed, and their viability was determined by the Trypan blue dyeexclusion method.
1.072-g/ml gradients (Badie and Schartner, 2000; Ford et al., 1995) . The microglia were found to express MHC I and II as well as costimulatory molecules. Most evidence for microglia cytokine production has come from immortalized human microglia cell lines that express the genes encoding IL-1b, IL-6, IL-8, IL-10, IL-12, IL-15, tumor necrosis factor a (TNF-a), and TGF-b (Nagai et al., 2001 ) and may not accurately depict the cytokine profile in GIMs.
In our study, we identify microglia/macrophages as the largest subpopulation infiltrating human gliomas. The GIMs do not produce cytokines reflective of activation despite known elaboration of TLR ligands by the glioma (Nakagawa et al., 1996; Steck et al., 1989) . Furthermore, GIMs lack the essential costimulatory molecules CD80, CD86, and CD40, thus failing to provide adequate intratumoral T-cell stimulation, which was consistent with the failure of GIMs to activate T cells in an allogeneic mixed-lymphocyte reaction (allo-MLR). In addition, the in vivo phenotypes of glioma-infiltrating T cells were predominantly CD81CD25-T cells and CD41CD251FOXP31 regulatory T cells.
Materials and Methods

Patients
Patients' tumors (n 5 50) were graded pathologically as GBM by a neuropathologist according to the WHO classification. Fresh normal brain tissue (n 5 6) can only rarely be obtained, since for most patients, efforts are made by the neurosurgeon to preserve this tissue. On occasion, normal brain tissue was obtained during an approach to a benign tumor such as a sphenoid wing meningioma, a well-circumscribed metastasis, or a low-grade lesion such as an oligodendroglioma. Additionally, peritumoral GBM tissue was obtained and separately analyzed; however, because this tissue could harbor microscopic tumor, it was not characterized as normal for the purposes of this study. The resected normal tissue demonstrated no evidence of increased signal on flair MRI preoperative imaging, and the brain tissue architecture was intraoperatively inspected microscopically by an experienced neurosurgeon (A.B.H.) and found to be consistent with that of normal brain tissue prior to submission to the laboratory. Peripheral blood was drawn from the patients intraoperatively. This study was conducted under protocol no. LAB03-0687, which was approved by the institutional review board of the University of Texas M.D. Anderson Cancer Center, and informed consent was obtained.
Antibodies
The cell surface was stained with phycoerythrin (PE)-labeled, fluorescein isothiocyanate (FITC)-labeled, or allophycocyanin-labeled antibodies against the following proteins: CD3, CD4, CD8, CD11b, CD11c, CD14, CD16, CD19, CD25, CD32, CD40, CD45, CD56, CD80, and CD86 (Pharmingen, San Diego, Calif.); Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/8/3/261/1039800 by guest on 11 March 2019 Fig. 1 . Gating strategy for immune cell analysis from CNS tissue. Cells were stained with IgG1-FITC, IgG1-PE, and IgG1-APC (isotype control) or CD1c-FITC, CD11c-PE, and BDCA-2-APC (stained) to identify myeloid DCs. In this example, GBM cells were analyzed by using a side-scatter versus forward-scatter dot plot on both the isotype (A) and stained cells (B) to select live cells (G1). The G1 gate was then applied to a CD11c versus CD1c dot plot (D) and its corresponding isotype (C). A statistical gate (G2) was drawn to indicate the CD11c1CD1c1 double positive (C and D). In the alternative gating strategy, isotype cells (E) and stained cells (F) were plotted on side scatter versus FITC, and FITC1 cells were gated (gate G3). By using the G3 gate, isotype and stained cells were analyzed on a CD11c versus CD1c dot plot (G and H, respectively) . A statistical gate (G4) was drawn to indicate the CD11c1CD1c1 population. Percentages in C and D and in G and H indicate the percentage of cells within G2 or G4, respectively. 
Prioritization of Characterization
Microglia/macrophages could never be isolated in sufficient numbers from a single GBM specimen to perform all of the assays concurrently. Furthermore, there is significant variability in the numbers of microglia/ macrophages obtained from each clinical specimen that could not be predicted preoperatively. A minimum of 5 g of tissue was necessary in order to isolate sufficient microglia/macrophages for the basic phenotypic characterizations. Purity was established on all specimens regardless of the assay priority. Fresh surgical tissue was analyzed as follows: (1) If large numbers (3-4 million) of microglia/macrophages could be generated from a GBM specimen (.10 g), the priority went to performing the allogeneic mixed-lymphocyte responses, and routinely drawn intraoperative peripheral blood was accessed for the controls. (2) For specimens .5 g, the microglia/ macrophages were analyzed for MHC and costimulator molecules, then intracellular cytokine analysis, then TLR expression, and then TLR responses to incubation with LPS-FITC. (3) For specimens ,5 g, priority went to performing the characterization of the immune cells infiltrating the unprocessed glioma or normal brain tissue.
Surface Marker and Intracellular Cytokine Staining
Microglia/macrophages were blocked for nonspecific binding by using purified anti-CD16 antibody (Pharmingen) for 20 min, and after washing, the cells were incubated with the fluorescence-labeled primary antibody or isotype control for 30 min at 4°C. For the intracellular cytokine analysis, microglia/macrophages were fixed with Cytofix/Cytoperm (BD Biosciences), washed in PermWash (BD Biosciences), and then stained with fluorescence-labeled monoclonal antibodies or isotype controls for 30 min at 4°C. Positive controls for all of the monoclonal antibodies consisted of either stimulated human lymphocytes (Pharmingen) or A375 cells (E.G.). Approximately 1 3 10 4 live, gated events were assessed during FACS by using an Epics XL-MCL cytometer (Beckman-Coulter, Fullerton, Calif.) and analyzed with IsoContour software (Verity Software House, Turramurra, Australia).
For the FOXP3 intracellular staining, the cells were first surface stained as described above with CD4 and CD25, followed by fixation and permeabilization with the respective buffers (eBiosciences), and then stained with FOXP3 antibody or the respective isotype control for 30 min at 4°C. Cells were analyzed with a FACSCalibur flow cytometer with CellQuest software.
Allogeneic Mixed Lymphocyte Responses
Stimulator cells were either microglia/macrophages isolated from patients' tumors as described above or APCs isolated from the peripheral blood of the respective glioma patients as follows. The buffy layer was isolated from patient peripheral blood after Ficoll density centrifugation. Cells were washed and labeled with CD3 microbeads (Miltenyi Biotec) at 20 ml/10 7 cells for 15 min at 4°C. The cells were washed and passed through a magnetic separation column (LD MACS Column; Miltenyi Biotec) placed in the magnetic field of a MACS separator (Miltenyi Biotec). Magnetically labeled CD31 cells were retained on the column while the unlabeled cell fraction that was CD3-ran through. Those CD3-cells were washed and determined by flow cytometry staining to be 97% pure for CD141, CD191, CD11c1, CD11b1, MHC II1, and CD3-cells. Responder T cells from peripheral blood obtained from a normal donor were isolated, stained with CD3 microbeads, and separated as described above, except that the unlabeled CD3-cells were allowed to run through, the column was washed, and the magnetically labeled CD31 fraction was flushed from the column. The CD31 cells were washed and determined to be 97% T cells by flow cytometry. Responder T cells were incubated with carboxyfluorescein diacetate succinimidyl ester (CFSE) for 15 min and washed thoroughly. Responder T cells were then labeled with CFSE as described earlier under the Antibodies section. For the mixed-lymphocyte reaction, in a 96-well plate, CFSE-labeled responder allo-T cells (0.75 3 10 5 cells/50 ml/well) were added to the patient stimulators (2.25 3 10 5 cells/50 ml/well) with or without LPS (5 mg/ml) (purified LPS [smooth] from Escherichia coli 0111:B4; Sigma-Aldrich Corp., St. Louis, Mo.) and incubated for four days at 37°C, 5% CO 2 . Controls included T cells incubated in media alone, each stimulator in media alone, and T cells stimulated with 5 mg/ml of purified anti-CD3 antibody (Pharmingen). Following incubation, cells were labeled with PE-anti-CD3 antibody to further gate out the CFSE-labeled responder T cells for analysis by FACS.
LPS-FITC Binding to TLR
Purified microglia/macrophages (5 3 10 5 /well) isolated from patients' glioma tissue were incubated with 1 mg/ml of LPS-FITC (purified LPS [smooth] from E. coli 0111: B4 conjugated with FITC; Sigma-Aldrich Corp.) for 5-min and 30-min incubation periods at 37°C, 5% CO 2 . Following incubation, cells were washed thoroughly in staining buffer and stained with TLR-4. Appropriate controls included cells stained with the isotype control for TLR-4 and cells incubated in media alone with no LPS-FITC stimulation.
Results
Flow Cytometry Gating Strategy to Identify Rare Cell Populations in Glioma Tissue
Tumor suspensions are markedly heterogeneous. Secondary to the rarity of the immune cells within these specimens, we used a specific flow cytometry approach to identify these cells in glioma tissue. In Fig. 1 , as a representative sample, we demonstrate our flow cytometry strategy for analysis of CD11c1CD1c1 M-DC from glioma tissue. On a side-scatter versus forward-scatter plot, dead cells were excluded when using gate G1 on both the isotype (Fig. 1A) and surface marker-stained cells (Fig. 1B) . We then applied this G1 gate on a CD11c versus CD1c dot plot and its corresponding isotype ( Fig.  1D and C, respectively). A quadrant gate was drawn on the CD11c versus CD1c dot plot based on the isotype control to exclude the double-negative-stained cells. A statistical gate (G2) was then drawn to identify the CD11c1CD1c1 double-positive population in the upper right quadrant. The G2 gate excludes the autofluorescent population that is seen in human CNS tissue suspensions (Watters et al., 2005) . Some of the double-positive cells may be lost in the autofluorescent population; however, the number of autofluorescent cells in the stained specimens and that in the corresponding isotypes remain almost identical. Therefore, we excluded this population in our analysis of double-positive cells. In addition, with the same compensation settings, single-stained (with only one fluorochrome marker) tumor samples that are similarly analyzed show distinct positive cell populations in the respective upper left or lower right quadrant (data not shown).
Since the double-positive cells are rare in CNS tissues (0.2% [ Fig. 1D] ) and can appear masked by the abundant background cells, to identify these immune cells successfully and gain a better perspective on their distribution in glioma tissue, we adopted a different gating strategy that enabled us to focus solely on these infrequent events. As shown in Fig. 1E -H, we analyzed the data on a side-scatter versus FITC plot. The gate for the FITC1 cells (G3) included only the CD1c-FITC1 cells (Fig. 1F ) when compared to the isotype control (Fig. 1E ). This G3 gate (CD1c1 cells) was then applied to a CD11c versus CD1c dot plot and its corresponding isotype ( Fig. 1H and G, respectively) . Finally, a statistical gate (G4) was drawn to identify the CD11c1CD1c1 doublepositive population in the upper right quadrant of these two plots but to exclude the autofluorescent population ( Fig. 1G and H) . The same gating strategy was used in Fig. 1E-H Fig. 2 and described under the section Intratumoral T Cells.
Characterization of the Immune Cells Infiltrating Human Gliomas
To determine the different subsets of immune cells within human gliomas, we stained freshly isolated patient glioma tissue with fluorescence-labeled antibodies to specific surface markers. In the glioma, we found a predominant population of microglia/macrophages ( Fig. 2A and Table 1 ). In contrast, microglia/macrophages were present in strikingly lower numbers in normal brain tissue, emphasizing the infiltration of these cells into glioma tissue. In GBM specimens, we observed far fewer infiltrating DCs relative to microglia/macrophages; in comparison to normal tissue, DCs were more common relative to microglia/macrophages. However, 20% of the CD11c1 gated cells were M-DCs (CD1c1) in GBM specimens, which was significantly greater than that seen in normal brain tissue (1% CD1c1CD11c1 gated cells) (Fig. 2B) and represented an absolute increase the in total number of M-DCs in GBM as compared to that in normal brain tissue (Table 1) . In contrast, 2% of BDCA-21 gated cells were P-DCs (CD11c-) in GBM specimens, which was less than that seen in normal brain tissue (15%) (Fig.  2C ), but this does not represent an absolute increase in the total number of P-DCs (Table 1) . B cells were infrequent in both GBM and normal tissue (MHC class II1CD191) (Fig. 2D) . As expected, the GBM tissue contained both infiltrating CD41 and CD81 T cells (Fig.  2E) . Since the majority of intratumoral immune cells were microglia/macrophages, we proceeded to a more detailed analysis of these cells, including an assessment of phenotype and functional capabilities to participate in innate and adaptive immune responses.
Purity of Microglia/Macrophages Isolated from Human Gliomas
To obtain human microglia/macrophages, we performed a series of Percoll-gradient purifications from normal human brain tissue and from freshly resected human glioma tissue. To determine the purity of our microglia/ macrophage isolation following Percoll-gradient purification, cells were stained with fluorescence-labeled antibodies to CD11b, CD11c, and CD45. We observed the largest population of CD11b/c1CD451 cells at the interphase between the 1.03-g/ml and 1.065-g/ml gradients (Fig. 3A) , unlike in the rodent studies, where the interphase between the 1.065-g/ml and 1.072-g/ml gradients was determined to contain the largest fraction of CD11b/ c1CD451 cells (Ford et al., 1995) . The expression levels of CD45 and CD11b/c were not significantly different in the cells isolated from each interphase (Fig. 3A) . Thus, in contrast to the rodent purification of microglia/ macrophages in which distinct CD11b/c1CD45High and CD11b/c1CD45Low cells were identified (Ford et al., 1995) , our purifications of human microglia did not reveal this heterogeneity in any GBM or normal brain tumor specimens. The human GIMs expressed Fc receptor II (FcR II) and FcR III, as expected (Fig. 3B ). All the GIMs were positive for CD14 expression (Fig. 3C) , an activation marker that plays a critical role in LPS-mediated TLR-4 activation. To characterize the cell populations from each interphase further, the cell populations were also stained with antibodies to CD3, CD4, CD8, CD56, and BDCA-21 and found to be negative for B cells, T cells, natural killer (NK) cells, and DCs (Fig. 3D and data not shown). The average yield of microglia/macrophages isolated from human GBM was 3.2 3 10 6 cells per gram of tumor (range, 1.8 3 10 5 to 3.7 3 10 7 cells/g; n 5 15) but was only 1.4 3 10 5 cells per gram of normal brain (range, 4.6 3 10 4 to 3 3 10 5 ; n 5 5). This represented an average, although highly variable, 30% recovery and a 60-fold enrichment of the microglia/macrophages. The purity of GIM isolated from human glioma specimens can vary because of disparities in each excised individual tissue sample.
TLR Expression on GIM
To determine whether GIM expressed the TLRs, we stained the purified GIM with fluorescence-labeled antibodies to TLR-1, -2, -3, and -4. Although TLR-1 was not expressed at significant levels, TLR-2, -3, and -4 were highly expressed on GIM as determined by fluorescence intensity. Similar expression levels of fluorescent intensity of TLRs were found on microglia/macrophages isolated from normal brain tissue (Fig. 4 and Table 2) or from microglia/macrophages obtained from peritumoral GBM (data not shown).
Intracellular Cytokine Analysis of GIMs
To determine if the microglia/macrophages are activated and elaborating cytokines that may modulate immune responses, intracellular cytokine analysis was performed for IL-1b, IL-6, IL-10, IL-12, IFN-, and TNF-a. GIMs demonstrated significant production of only IL-12 (Fig.  5 and Table 2 ) when compared to the production other cytokines. However, this production of IL-12 was no different from the intracellular cytokine production in microglia/macrophages from normal brain (n 5 3). All other cytokines (i.e., IL-1, IL-10, and TNF-a) were either found at minimal levels or were absent.
GIM Expression of MHC but Not Costimulatory Molecules
To determine whether GIM cells can participate in adaptive immunity as functional CNS APCs, these cells were analyzed for surface MHC and costimulatory molecule expression. Microglia/macrophages from GBM and those from normal tissue both express MHC class II (Fig. 6A and Table 2 ).
To establish whether microglia/macrophages express the costimulatory molecules, these cells were stained with fluorescence-labeled anti-CD80 and anti-CD86 antibodies. GIMs did not express CD80, whereas CD86 was largely absent but was expressed at more variable levels ( Fig. 6B and C) . These findings were comparable to those seen in microglia/macrophages isolated from normal brain tissue and from peritumoral GBM microglia/ macrophages. In addition, CD40 was not expressed on the GIM cell surface (n 5 12) (Fig. 6D) . Collectively, these findings indicate that GIMs do not express the costimulatory molecules necessary for them to participate in adaptive immunity.
Functional Capabilities of GIMs to Stimulate T-Cell Responses
To determine if the lack of surface expression of costimulatory molecules on GIMs affected their ability to stimulate T cells, allo-MLRs were performed with either patient GIMs or APCs isolated from the patient's peripheral blood as stimulators and allogeneic T cells from a normal donor as responders. Negligible proliferation (2%) was seen in T cells without an activated APC population (Fig. 7A) . The addition of the peripheral blood APCs enhanced T-cell proliferation slightly (9%) and was likely nonspecific activation (Fig. 7B) . However, there was marked T-cell proliferation when the APCs were activated with LPS (36%) or the T cells activated with anti-CD3 antibody (48%) (Fig. 7B and A,  respectively) . In marked contrast, GIMs were incapable of inducing significant T-cell stimulation, regardless of whether they were stimulated by LPS; T-cell proliferation remained similar to baseline levels (8% vs. 9%) (Fig.  7C) .
Binding of LPS to TLR-4 on GIMs
GIMs express significant levels of the LPS receptors TLR-4 and CD14 (Fig. 4 and 3C, respectively) . To determine whether GIMs are unresponsive to LPSmediated stimulation because of the inability of LPS to actually bind the TLR-4 receptor, we incubated freshly isolated GIMs with FITC-conjugated LPS. LPS binding is detected on the surface of GIMs when compared to cells not stimulated with LPS (Fig. 8A ) and appears to be present only on the cells expressing TLR-4 (Fig. 8B) . Similar data were obtained for LPS binding via CD14 (data not shown).
Intratumoral T Cells
Since GIM produced IL-12, a CD81 T-cell-stimulating cytokine, we wanted to determine if there was a population of activated tumor-infiltrating T cells in the gliomas. Gliomas were dissociated and stained for the CD81 and CD41 subsets (Fig. 9A) . The tumor-infiltrating CD81 T cells were phenotypically CD81CD25- (Fig. 9B) , which indicated that these cells were not activated. CD41 T cells were more numerous than CD81 T cells within glioma tissue (20% vs. 11% gated lymphocytes) (Fig . Fig. 4 . Expression of TLR on GIM and microglia/macrophages isolated from normal brain. Purified microglia/macrophages from GBM tissue and normal brain tissue were double-stained for CD45 and TLR expression. An autofluorescent population was identified in both normal and GBM tissue samples during flow cytometry analysis and is also consistently present in the respective isotype controls. This population was excluded when calculating the percentages of positive fluorescing cells. Abbreviations: CD, cluster of differentiation; GBM, glioblastoma multiforme; IFN, interferon; IL, interleukin; TLR, Toll-like receptor; TNF, tumor necrosis factor.
*The percentage of positive cells was calculated after subtracting for isotype staining as previously described. All cells were gated on either CD11b+ or CD45+ (both markers are expressed on microglia) out of a total of 30,000 analyzed cells. There was no statistically significant difference in the levels of surface marker expression between gliomainfiltrating microglia and microglia from normal brain tissue.
9C), and a significant number were also CD251, which indicated possible regulatory T-cell phenotype. This was confirmed by demonstrating that glioma-infiltrating CD41 T cells, as well as peripheral blood CD41 T cells from patients, were not only CD251 but also positive for the intracellular marker FOXP3 (Fig. 9D) , a transcription factor that is elevated only in regulatory T cells (T reg cells) and not in activated effector CD41 T cells (Fontenot and Rudensky, 2005) .
Discussion
For the first time, we have isolated human microglia/ macrophages from human brain and malignant gliomas and examined their phenotype and function. In stark contrast to the identification of distinct CD45Low and CD45High subpopulations in rodent studies, in our study, these subpopulations were not identified in microglia/macrophages isolated from human glioma tissue as has been previously suggested (Watters et al., 2005) . Macrophages are considered to be activated microglia, and thus our isolated "microglia" may all be activated within the malignant glioma. However, we would have anticipated that these subpopulations would be identified in the "microglia" isolated from normal brain without any type of initiator for inflammation. Alternatively, this distinction may be artifactual to the monoclonal antibodies or to the model system. Our data indicate that the cells we have isolated are not contaminated with other immune cells such as B cells, T cells, NK cells, or DCs. Previous investigators (Ford et al., 1995) determined in their studies on normal rodent brains that the CD45HighCD11b/c1 cells classified as macrophages had significant APC activity, whereas the CD45Low CD11b/c1 microglia clearly did not. Although we cannot definitely determine whether our isolated population from human brain tissue represents microglia or macrophages or a cell population within the continuum, it is clear from our data that none of the cells isolated have functional APC activity or APC phenotype, which reinforces the possibility that the cells are mostly microglia. Since these cells are clearly very prominent and common within malignant gliomas, their role in controlling immunological responses within the CNS is nonetheless important, especially in the setting of immunotherapeutic approaches. Within human gliomas, microglia/macrophages are a predominant immune subset. However, they do not appear to be fully able to modulate innate and adaptive immune responses. Activation of innate immunity triggers cytokine production and the subsequent activation of adaptive immune responses (Akira et al., 2001; Ito et al., 2002) that are essential for tumor eradication/ suppression. Although it has been argued that tumors fail to provide sufficient pro-inflammatory responses, others have suggested otherwise (Matzinger, 1994; Pardoll, 2003) . Factors that induce innate immune responses similar to microbial pathogens include heat shock proteins (Asea et al., 2002; Ohashi et al., 2000; Srivastava, 2002) , hyaluronic acid (Termeer et al., 2002) , and heparin sulfates (Johnson et al., 2002) , which are all prodigiously produced by gliomas (Glimelius et al., 1978; Nakagawa et al., 1996; Neuhaus-Steinmetz and Rens-ing, 1997; Steck et al., 1989) . These factors are TLR-4 agonists (Beg, 2002; Habich et al., 2002; Kakimura et al., 2002) , and although TLR-4 is expressed on GIM cells, we were surprised to find that, unlike the GIMs of the murine system (Ebert et al., 2005) , these human GIMs did not express cytokines that would be reflective of the innate immune arm being activated. Instead, the cytokine profile of GIMs is similar to that of resting microglia isolated from normal brain tissue, which suggests that TLR agonists within malignant gliomas do not activate GIMs. Furthermore, LPS, a known TLR-4 agonist and stimulator of murine microglia activity (Ebert et al., 2005) , did not improve the ability of GIMs to stimulate allogeneic T cells in vitro. We cannot exclude the possibilities that activation of the innate immune system could occur with alternative TLR agonists, cytokine- Fig. 5 . Cytokine production by GIM and microglia/macrophages isolated from normal brain. Purified microglia/macrophages were freshly isolated from GBM tissue and stained for the intracellular cytokines IL-6, IL-10, IL-12, TNF-a, and IFN- without in vitro stimulation. Cytokines were detected by using fluorescence-labeled antibodies and analyzed by flow cytometry. Positive intracellular cytokine expression was confirmed for all cytokines in either a reporter cell line (A375) or stimulated lymphocytes (data not shown). Microglia/macrophages isolated from normal brain were also analyzed for the same cytokine expression profile.
Downloaded from https://academic.oup.com/neuro-oncology/article-abstract/8/3/261/1039800 by guest on 11 March 2019 mediated stimulation, or even alternative CNS cells. Finally, despite the presence of TLR-4 and its ability to bind its agonist LPS, the GIMs are apparently unresponsive to LPS-induced stimulation, which suggests a breakdown of key signaling pathways following the triggering of the TLR-4-CD14 complex. Studies are currently under way to ascertain if the failure of LPS response despite adequate expression of TLR is secondary to a breakdown in signaling pathways following triggering of the TLR-4-CD14 complex. The use of TLR agonists for immunotherapy in glioma patients needs to be carefully considered because this may not necessarily result in activation, especially in the presence of immunosuppressive cytokines. Although GIM and microglia/macrophages isolated from normal brain tissue express MHC class II, neither population expressed significant levels of costim- ulatory molecules. The expression of these costimulatory molecules and that of MHC appear to vary between species, model systems, and disease states. Previously, human microglia have been shown to express CD86 but not CD80 during autoimmunity (multiple sclerosis) and infection (HIV) (Dangond et al., 1997; Satoh et al., 1995) . On the other hand, parenchymal microglia from normal adult mice express high levels of CD80, CD86, and MHC class II (Zhang et al., 2002) , while parenchymal microglia from normal rat brains express high levels of CD86 but not CD80 or MHC class II (Badie et al., 2002) . Since T-cell activation requires signals through both MHC and costimulatory molecules, the expression of MHC alone on microglia/macrophages would not activate a T-cell response but could result in T-cell anergy (Hu et al., 2002; Yi-qun et al., 1997) , which has previously been proposed as the means by which gliomas elude immune defense despite the presence of antigenic stimuli. Murine microglia expressing low levels of costimulatory molecules have been unable to activate either naive or primed T cells and can induce T-cell anergy (Matyszak et al., 1999) . Indeed, our in vitro data from the allo-MLR indicate that human GIMs are unable to activate T cells effectively, and ex vivo analyses of the glioma infiltrate show a marked absence of activated CD8 T cells (CD81CD251). This phenomenon appears to occur despite the presumed secretion of IL-12 by the isolated GIMs. IL-12 is a potent stimulator of effector CD8 T cells. However, studies have previously shown that once T-cell anergy has been established, IL-12 alone is unable to reverse this state and that it takes additional factors such as CTLA4 blockade to reverse this anergy (Andrews et al., 1997; Quill et al., 1994; Van Parijs et al., 1997) . We can not exclude the possibility that the rare DCs identified within the gliomas could act as APCs mediating immune responses within the immunosuppressive environment, especially since recent studies in murine experimental allergic encephalomyelitis models have described a minority population of CNS DCs that were adequate to restimulate adoptively transferred antigen-experienced effector cells (Greter et al., 2005; McMahon et al., 2005) . Immune recognition of gliomas appears to have occurred, as evidenced by the presence CD41 and CD81 T cells within the glioma. If T cells were passively present, secondary to the breakdown of the bloodbrain barrier, we would have expected a similar ratio of CD41 to CD81 T cells seen in peripheral blood, but this was not the case. Instead, there was an elevated CD41 T-cell population of a regulatory T-cell phenotype (CD41CD251FOXP31). Functionally, T reg cells can prevent the activation or expansion of both CD41 and CD81 T cells through mechanisms that are still poorly understood, but could involve the secretion of suppressive cytokines (IL-10 or TGF-b), the restraining of antigen-presenting capacity, or mediation of cell-to-cell contact inhibition (Karpus and Swanborg, 1991; Shevach et al., 2001) . Furthermore, T reg cells do not require costimulatory signals through the CD80/86 interaction to mediate their suppressor activity (Thornton et al., 2004) . They have been identified in the peripheral blood of glioma patients (Akasaki et al., 2004) and in the tumor microenvironment of other solid tumors, such as pancreatic, colon, lung, and breast adenocarcinomas (Liyanage et al., 2002; Woo et al., 2002) . However, we are the first laboratory to demonstrate the presence of T reg cells within malignant gliomas. Apart from inhibition of effector CD81 T-cell activity, T reg cells can also suppress pro-inflammatory cytokine production (TNF-a, IFN-, and IL-6); inhibit expression of MHC class II, CD40, CD80, and CD86; and impair antigen presentation by monocytes and macrophages (Misra et al., 2004; Taams et al., 2005) , phenomena similar to what we have demonstrated in our GIM population. Thus, in glioma patients, T reg cells appear to have a role in the lack of immune eradication or suppression of the tumor by modulating innate and adaptive immune responses (Mendez et al., 2004) . The T reg cells are probably physiologic in maintaining tolerance to self-antigens and minimizing inflammatory responses, especially when significant cerebral edema could be fatal. Overcoming T reg immune suppression may be a future therapeutic approach, albeit one that will have to be exploited cautiously through immunization strategies that incorporate tumor-specific antigen approaches. The significance of T reg cells in malignant glioma patients has yet to be determined, but their presence has been found to be a negative prognostic indicator within patients with ovarian carcinoma (Curiel et al., 2004) . Of note, microglia/macrophages failed to secrete the immunosuppressive cytokine IL-10 as has been previously suggested (Huettner et al., 1997) . Microglia/macrophages from human glioblastomas, identified solely by CD681 expression, were shown by in situ hybridization and IL-10 mRNA expression to secrete IL-10 (Wagner et al., 1999) . Although CD68 GBM cells were gated on CD81 expression (by using the R1 gate on Fig. 8A ) and examined for CD81CD251 expression (upper right quadrant). C. GBM CD41 T cells were gated (by using the R2 gate on Fig. 8A ) and examined for CD41CD251 expression in the upper right quadrant. D. GBM CD41 T cells were gated (by using the R2 gate on Fig. 8A ) and examined for FOXP3 expression in the upper right quadrant. E. Patients' PBMCs were gated on lymphocytes by size and density and examined for CD41 (upper left quadrant) and CD81 (lower right quadrant) expression. F. PBMCs were gated on CD81 expression (by using the R3 gate on Fig. 8A ) and examined for CD81CD251 expression (upper right quadrant). G. PBMC CD41 T cells were gated (by using the R4 gate on Fig. 8A ) and examined for CD41CD251 expression in the upper right quadrant. H. PBMC CD41 T cells were gated (by using the R4 gate on Fig. 8A ) and examined for FOXP3 expression in the upper right quadrant. antigen is expressed by tissue macrophages and cells of myeloid/mononuclear lineage, it is also constitutively expressed in NK cells, gamma/delta T cells, and activated CD41 and CD81 T cells (Hameed et al., 1994) , which suggests that the aforementioned IL-10 secretion could be from nonmicroglial cells such as Th2 CD41 T cells or T reg cells.
Together, these data demonstrate that while microglia/ macrophages are the largest immune cell population infiltrating human glioma tissue, they are likely acting in an inherent regulatory mechanism by which rapid intracerebral T-cell expansion is prevented in the CNS microenvironment. This suppressive activity may be bolstered or even induced by the action of the CD41CD251 T reg cells also present in the glioma tissue, affecting subsequent innate and adaptive immune responses. Accumulating evidence indicates that immune recognition of tumors occurs (Dunn et al., 2004) . However, our data indicate that negative immunoregulation is occurring within the tumor microenvironment. Thus, treatments directed at improving antitumor responses will need to consider these two key populations, thereby reinforcing the importance of the complexities involved in immune interactions within the glioma microenvironment.
